You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Xellia Pharms Aps Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for XELLIA PHARMS APS, and when can generic versions of XELLIA PHARMS APS drugs launch?

XELLIA PHARMS APS has sixteen approved drugs.

There are seven US patents protecting XELLIA PHARMS APS drugs.

There are fifty patent family members on XELLIA PHARMS APS drugs in thirty countries and twenty-eight supplementary protection certificates in nine countries.

Summary for Xellia Pharms Aps
International Patents:50
US Patents:7
Tradenames:10
Ingredients:10
NDAs:16

Drugs and US Patents for Xellia Pharms Aps

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-007 May 13, 2020 RX Yes Yes 10,849,956 ⤷  Try a Trial Y ⤷  Try a Trial
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-006 May 13, 2020 RX Yes Yes 10,188,697 ⤷  Try a Trial Y ⤷  Try a Trial
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-001 Feb 15, 2019 RX Yes Yes 10,039,804 ⤷  Try a Trial Y ⤷  Try a Trial
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride INJECTABLE;INJECTION 091377-001 Sep 9, 2015 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride INJECTABLE;INJECTION 206243-002 Dec 23, 2015 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Xellia Pharms Aps TIGECYCLINE tigecycline POWDER;INTRAVENOUS 205722-001 Oct 18, 2019 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Xellia Pharms Aps Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1280520 C01280520/01 Switzerland ⤷  Try a Trial PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 60565 01.02.2012
0440372 SPC/GB02/031 United Kingdom ⤷  Try a Trial PRODUCT NAME: VORICONAZOLE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/02/212/001-025 20020319
0620232 01C0054 France ⤷  Try a Trial PRODUCT NAME: CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001 20011024
0536515 SPC/GB06/033 United Kingdom ⤷  Try a Trial PRODUCT NAME: TIGECYCLINE
0620232 SPC/GB02/002 United Kingdom ⤷  Try a Trial A SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016.
0440372 02C0030 France ⤷  Try a Trial PRODUCT NAME: VORICONAZOLE; NAT. REGISTRATION NO/DATE: EU/1/02/212/001-025 20020319; FIRST REGISTRATION: EU/1/02/212/001-25 20020319
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.